REG - Oxford Biomedica PLC - Compliance with LR 9.2.6ER(1)

Oxford BioMedicaAnnouncement

28/04/2020 13:05

RNS Number : 1894L
  
Oxford Biomedica PLC
  
28 April 2020
  
 

 
 
 
Oxford Biomedica 
Information disclosed in accordance with LR 9.2.6ER(1)
 
 
Oxford, UK - 28 April 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that in compliance with Listing Rule 9.2.6ER(1), the Company has forwarded to the FCA for publication a copy of its Articles of Association, which is the document that sets out the terms and conditions on which its listed equity shares were issued.
 
A copy of the Company's Articles of Association has been submitted to the National Storage Mechanism and will be available for inspection shortly at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
 
-Ends-
 



For further information, please contact:


 




 
Oxford Biomedica plc:
Natalie Walter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCEAALPAEAEEFA